The Italian Administrative Tribunal fines two pharmaceutical companies for colluding to create an artificial product differentiation in order to influence the prescriptions of doctors and health services in favor of the more expensive product (Roche, Novartis)

Italian court confirms hefty fines on Novartis and Roche* On 2 December 2014, Italy’s Tribunale Amministrativo Regionale del Lazio (“TAR Lazio”) handed down its ruling (only available in Italian) concerning the alleged anticompetitive agreement between Roche and Novartis in the market for ophthalmic drugs used to treat some serious vascular eyesight conditions, which, in its decision of 27 February 2014, the Italian Competition Authority (“ICA”) found to be in breach of article 101 of the Treaty on the Functioning of the European Union (“TFEU”), and imposed fines totaling Euro 92 million and Euro 90,5 million on Novartis and Roche respectively (see Newsletter 2/2014 p. 18 and Newsletter 1/2013, p. 11,

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

Quotation

Gabriele Accardo, The Italian Administrative Tribunal fines two pharmaceutical companies for colluding to create an artificial product differentiation in order to influence the prescriptions of doctors and health services in favor of the more expensive product (Roche, Novartis), 2 December 2014, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 72180

Visites 106

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues